Full Text
PCN28 ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2-3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER- A FINNISH PERSPECTIVE

Abstract

Authors

N Fàrkkilà T Kotomäki V Jormanainen

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×